|
>
FLASH REPORT
Burgeoning commerce in
China is outpacing its ability to fill high-ranking
posts. Frank Waltmann, Head of Learning at Novartis,
describes the major challenges in China and how
Novartis is taking proactive steps to address them.
Novartis
Invests in China
Michael P. Czech, Ph.D.,
a Professor and Chair for the Program in Molecular
Medicine at University of Massachusetts Medical School, talked to Pharma DD about recent
publications using RNAi as a screening tool.
Using
RNAi To Screen for Drug Targets in Metabolic
Diseases
>
STRATEGIC
BRIEFINGS
Microwave-based
chemical synthesis for small-molecule drug discovery
offers several advantages. Medicinal chemists are
finding they can use microwave energy to catalyze a
broad range of chemistries. By putting a moderate
amount of energy into a reaction to drive chemical
transformations, they can achieve higher yields and
greater purity, and realize significant improvements
in efficiency and productivity.
Microwave-Driven
Compound Synthesis: Turning Up the Heat on Med Chem
By Vicki Glaser, February 14, 2007
The
market opportunity is untapped, and the time is now.
The race is on for a treatment that can modify
Alzheimer’s disease. The number of Americans with
Alzheimer’s could grow to as many as 16 million by
2050. We examine some of the efforts that are
underway to develop new treatments for Alzheimer’s
disease. The product candidates in late-stage
clinical development reveal that companies are
pursuing a wide range of approaches and targets in
this endeavor.
Companies
Sprint toward Alzheimer’s Disease–Modifying Drug
By Lucy Sannes, Ph.D., Sannes & Associates,
December 7, 2006
The
therapeutic and commercial potentials for using
potent immunomodulatory agents to boost or suppress
autoimmune responses continue to grow enormously. Immunomodulators
that
target
tumor
necrosis
factor
(TNF)-alpha
alone
had
combined
worldwide
sales
of
over
$8.5 billion
in 2005, demonstrating the large market potential
for this
class of agents.
Breakthrough
Immune Modulator Targets Have Blockbuster Potential
By Lucy Sannes, Ph.D., Sannes & Associates,
November 30, 2006
Vicki Glaser, Contributing Editor to Pharma DD,
contributed to this article.
Monoclonal
antibody–based therapies have proven to be major
clinical and marketing successes. Six of the
antibodies on the market in the U.S. today have already reached blockbuster status, with
sales exceeding $1 billion each. Antibodies
currently on the market in the U.S.
had combined global sales greater than $13 billion
in 2005.
Monoclonal
Antibodies: From Magic Bullets to Successful Drugs
By Lucy Sannes, Ph.D., Sannes & Associates,
November 16, 2006
Vicki Glaser, Contributing Editor to Pharma DD,
contributed to this article.
C-reactive
protein (CRP) has attracted considerable attention as
a biomarker for cardiovascular disease risk. In
addition, interest in CRP as a potential drug target
continues to grow. If clinical data ultimately
demonstrate that CRP is a reliable biomarker for
cardiovascular disease and is a useful therapeutic
target, novel drugs developed to modulate CRP levels
and activity have the potential to be blockbuster
drugs with annual sales of multiple
billions of dollars.
C-Reactive
Protein--Cardiac Risk Marker and Potential Drug
Target
By Lucy Sannes, Ph.D., Sannes & Associates,
November 9, 2006
Vicki Glaser, Contributing Editor to Pharma DD,
contributed to this article.
More
Strategic Briefings
Evista:
Clinical Trial Results Question Its Safety and
Efficacy
Sucampo
Leverages Prostones Expertise, Files IPO
Recent
Clinical Developments in Type 2 Diabetes
Novartis'
Alex Gaither on How New Tools are Redefining
Chemogenomics
Emerging
HIV Therapies: Part 2 of 2
Emerging
HIV Therapies: Part 1 of 2
HIV/AIDS
Vaccines Pose Economic, Demographic, and Scientific
Challenges
Safety
Issues Hamper Dual PPAR Agonists: Is Partial
Antagonism the Solution?
Alzheimer's
Early Detection Strategies--From Skin to Sniff Tests
and Beyond
Renin Inhibitors Show Promise for Treating Hypertension
What’s Next for Stem Cell Companies?
Finding
the Magic in Fixed Combinations
Companies Race to Expand HCV Market Using Bold Approaches
Novartis Plunges into Hepatitis C Market
|
